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Abstract
Background:  Safe Psoriasis Control (SPC) is an important comprehensive measure that is
validated for the assessment of benefit:risk of psoriasis treatments, combining efficacy, quality of
life, and safety measures. The objective of this analysis was to assess the benefit:risk of efalizumab,
a novel biologic agent indicated for the treatment of moderate-to-severe plaque psoriasis, by
applying the SPC to data from randomized, placebo-controlled clinical studies of efalizumab.
Methods: SPC was applied to week 12 data from four placebo-controlled, Phase III studies: three
retrospective and one prospective, the latter including a cohort of "high-need" patients for whom
existing therapies were inadequate or unsuitable.
Results: In the retrospective analysis, 39.4% of patients achieved SPC after 12 weeks of treatment
with efalizumab, compared with 10.4% for placebo. In the prospective analysis, 34.3% of patients
achieved SPC after 12 weeks of treatment with efalizumab, compared with 7.3% on placebo.
Among high-need patients, 33.0% achieved SPC, compared with 3.4% on placebo.
Conclusion: Efalizumab has a favorable benefit:risk profile using the comprehensive outcome
measure SPC.
Background
Over the past decade, technological advancements have
resulted in a substantial increase in the number of new
molecules under investigation for the treatment of psoria-
sis. At the same time has come the realization that current
efficacy measures have significant limitations in assessing
the full therapeutic benefit of psoriasis therapies. Despite
its shortcomings, the most widely used measure to assess
efficacy of new therapies has remained the Psoriasis Area
and Severity Index (PASI) [1,2]. However, concerns
regarding this endpoint [3] and the lack of use of PASI in
current practice by dermatologists have resulted in the
development of alternative measures such as the Salford
Psoriasis Index (SPI) [4], the Self Administered PASI
(SAPASI) [5], the Koo-Menter Psoriasis Instrument [6],
and the National Psoriasis Foundation Psoriasis Score
(NPF-PS) [7].
To more fully evaluate and interpret the benefit:risk of
new therapies for psoriasis requires measures that assess
multiple dimensions of the disease in a clinically mean-
ingful way for patients and physicians alike. Safe Psoriasis
Control (SPC) [3] is such a measure that is designed to
improve relevance and comparability between studies
and drugs by focusing on all clinically relevant outcomes
so that accurate assessments can be made regarding new
therapies for psoriasis [8].
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SPC is an important advance in the evaluation of treat-
ments for psoriasis, and is a useful tool for evaluating the
short term benefit:risk profile of new drugs[3]. It is the
only assessment that takes into consideration the multiple
aspects of psoriasis and its treatment, simultaneously rec-
ognizing and incorporating the importance of physician-
based assessments of disease severity; patient-based
assessments of the impact of the disease; and the safety of
the drug.
The data used to derive and validate SPC were for the new
biological agent efalizumab, a humanized, recombinant,
monoclonal IgG1 antibody developed to target multiple T-
cell-mediated processes critical to the pathogenesis of pso-
riasis [9]. More than 3,500 patients have received efalizu-
mab as part of clinical trials for over 3 years, and the data
from approximately 2,500 of these were used in the deri-
vation of SPC.
The methodology to derive and validate SPC is discussed
in Papp et al [3]. Briefly, important components in the
assessment of therapeutic benefit were identified, fol-
lowed by an analysis to identify clinically meaningful
achievements in these components using a statistically
robust approach. Thereafter, the endpoint was further val-
idated using a combination of other statistical methodol-
ogies, external references, and prospectively in an
independent on-going live clinical trial setting.
The purpose of this analysis was to assess the benefit:risk
of efalizumab at 12 weeks by applying the SPC to data
from randomized, placebo-controlled clinical studies of
efalizumab.
Methods
As outlined in Papp et al [3], three levels of SPC are
described in order to demonstrate the accuracy, validity
and rigor of the multidimensional measure. Dimensions
are efficacy (assessed using PASI data), safety (assessed
using adverse events data), and quality of life, which is
assessed using data from the Dermatology Quality Life
Index (DLQI), a reliable and validated self-administered
dermatology quality of life instrument [10]. For this
paper, however, in recognition of the practical necessities
of normal clinical practice, only one was selected. Given
that a DLQI score of 6 is considered to represent a normal
quality of life [11], it was decided for practical clinical pur-
poses to use good SPC (defined as PASI score ≤8 and
DLQI score ≤6 with no SAEs and no severe AEs related to
study drug and not withdrawn) as the target endpoint.
In this paper, the good SPC endpoint was applied to efal-
izumab clinical trial data as described in the following sec-
tion (Table 1).
Retrospective application
SPC was applied retrospectively to week 12 data from
studies that had been completed prior to derivation of the
endpoint. In this regard, data analyses were performed on
the intention-to-treat (ITT) subject populations enrolled
into three North American randomized, placebo-control-
led, Phase III clinical trials of efalizumab (ACD 2058,
ACD 2059, and ACD 2390) [12-15]. Data from each study
were analyzed on an individual as well as pooled basis.
The first 12 weeks of all phase III trials were double-blind,
parallel group design. Efalizumab was given subcutane-
ously at 1 mg/kg/week.
Table 1: Studies used for retrospective and prospective application of SPC
Study Number Study Title Number of Patients Application analysis of Good 
Safe Psoriasis Control (SPC)
ACD 2058[14] "A Phase III, Randomized, Double-Blind, Parallel-
Group, Placebo-Controlled, Multicenter, Multidose 
Study to Evaluate the Efficacy and Safety of 
Subcutaneously Administered Anti-CD11a in Adults 
with Moderate to Severe Plaque Psoriasis"
498 subjects
•efalizumab 1 mg/kg – 162
•efalizumab 2 mg/kg – 166
•placebo – 170
Retrospective
ACD 2059[13] "A Phase III, Randomized, Double-Blind, Parallel-
Group, Placebo-Controlled, Multicenter, Multidose 
Study to Evaluate the Efficacy and Safety of 
Subcutaneously Administered Anti-CD11a in Adults 
with Moderate to Severe Plaque Psoriasis Who Are 
Candidates for Systemic Therapy"
597 subjects
•efalizumab 1 mg/kg – 232
•efalizumab 2 mg/kg – 243
•placebo – 122
Retrospective
ACD 2390[12] "A Phase IIIb, Randomized, Double-Blind, Parallel-
Group, Placebo-Controlled, Multicenter Study to 
Evaluate the Efficacy and Safety of 1.0 mg/kg 
Subcutaneously Administered Efalizumab in Adults 
with Moderate to Severe Plaque Psoriasis"
556 subjects
•efalizumab 1 mg/kg – 369
•placebo – 187
Retrospective
IMP 24011[15] "A multicentre, randomised, double blind, placebo 
controlled phase III study of subcutaneously 
administered Raptiva in the treatment of patients 
with moderate to severe psoriasis"
793 subjects
•efalizumab 1 mg/kg – 529
•placebo – 264
•(526 high-need)
ProspectiveBMC Dermatology 2006, 6:8 http://www.biomedcentral.com/1471-5945/6/8
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Prospective application
SPC was applied prospectively to week 12 data from stud-
ies that were completed after derivation of the endpoint.
For this paper data analyses were performed on the ITT
subject populations enrolled in an international rand-
omized, double-blind, placebo-controlled, parallel-
group, multicentre trial (IMP 24011, ClinicalTrial.gov reg-
istration number NCT00256139) consisting of an initial
12-week, double-blind treatment period. PASI 75
responders entered an observation period until relapse or
up to 24 weeks, after which patients received 12 weeks of
open-label re-treatment. Non-responders went directly to
an extended treatment period of 12 weeks. The primary
objective of the study was to evaluate the safety and effi-
cacy of efalizumab 1.0 mg kg-1 given subcutaneously once
weekly for 12 weeks compared with placebo in moderate-
to-severe patients, and in a cohort of "high-need" patients
for whom existing therapies were inadequate or unsuita-
ble. An initial cohort of moderate-to-severe patients was
recruited, on whom an interim analysis was performed
showing efalizumab efficacy versus placebo. After this,
only high-need patients were recruited.
High-need patients were defined as those patients who
had failed treatment on, were intolerant of, or had con-
traindications to at least two currently available systemic
therapies (e.g., photochemotherapy, cyclosporin, corti-
costeroids, methotrexate, oral retinoids, mycophenolate
mofetil, thioguanine, hydroxyurea, sirolimus, azathio-
prine, 6-mercaptopurine).
SPC was analyzed for the first 12-week treatment period
for which data are available.
Patients
Inclusion and exclusion criteria were similar for all studies
included in the analysis, except for the high-need cohort,
as already explained. Patients were required either to have
received previous systemic treatment for psoriasis or to be
a candidate for such treatment without prior history. All
patients enrolled were 18 to 75 years old with at least a 6-
month history of moderate-to-severe plaque psoriasis
covering ≥10% of total body surface area (BSA), with a
minimum PASI of 12.0 at screening.
The total number of all patients for the prospective analy-
sis using study IMP 24011 was 793, of whom 526 were
high-need patients.
Treatment
Study treatment efalizumab 1 mg/kg/week was adminis-
tered via subcutaneous injection once weekly for 12
weeks. The first weekly dose of efalizumab was given at a
conditioning dose of 0.7 mg kg-1, followed by the full
dose level of 1.0 mg kg-1. No other systemic psoriasis ther-
apy or phototherapy was allowed during the trial.
Assessment of benefit:risk
Conventional physician-assessed endpoint data such as
PASI, and patient outcome measures such as DLQI, were
collected for the 12-week timepoint. Safety was assessed
in terms of the incidence, severity, and relationship to
treatment of adverse events (including serious adverse
events) and the incidence of treatment-emergent labora-
tory abnormalities. SPC for efalizumab was calculated
from these 12-week data.
Results
Retrospective SPC analysis
Table 2 shows the SPC outcome data from the retrospec-
tive analyses. The results were similar between the studies.
At 12 weeks, SPC was achieved by 46.3%, 37.1%, and
37.9% of efalizumab-treated patients for studies ACD
2058, ACD 2059, and ACD 2390, respectively. When
pooled, 39.4% of patients achieved SPC at week 12, com-
pared with 10.4% for placebo.
Prospective SPC analysis in study IMP 24011
In the study IMP 24011, DLQI was administrated to 494
of the 793 patients (165 randomized to placebo and 329
to efalizumab 1.0 mg/kg/wk), as appropriately validated
translations of the questionnaire were not available for
use in Greece, Israel, Portugal or Russia. Thus, determina-
tion of the percentages of patients achieving SPC at week
Table 2: Retrospective SPC results (Good control level) at week 12
Study Treatment Group Safe Psoriasis Control (SPC)*
ACD2058[14] Placebo (n = 170) 18 (10.6 %)
Efalizumab 1.0 mg/kg/wk (n = 162) 75 (46.3 %)
ACD2059[13] Placebo (n = 122) 12 (9.8 %)
Efalizumab 1.0 mg/kg/wk (n = 232) 86 (37.1 %)
ACD2390[12] Placebo (n = 187) 20 (10.7 %)
Efalizumab 1.0 mg/kg/wk (n = 369) 140 (37.9 %)
Pooled studies Placebo (n = 479) 50 (10.4%)
Efalizumab 1.0 mg/kg/wk (n = 763) 301 (39.4%)
* SPC is defined by PASI <= 8 and DLQI <= 6 and No SAEs and No Severe AEs related to Study Drug and not withdrawnBMC Dermatology 2006, 6:8 http://www.biomedcentral.com/1471-5945/6/8
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12 was based on the cohort of patients for whom DLQI
was available. In these patients 34.3% of patients
achieved SPC on efalizumab, compared with 7.3% on pla-
cebo (Table 3).
In high-need patients, only 4/117 patients (3.4%) given
placebo achieved SPC at week 12, compared with 73/221
(33.0%) on efalizumab (Figure 1).
Observed response rates at week 12 were lower in the pro-
spective validation compared with the retrospective rates.
However, the rate differences between active and placebo
observed in the prospective study (27% for the total study
group and 30% for the high need group) were similar to
that seen in the retrospective analyses (29%).
Comparison of PASI-75 and SPC
The efficacy-only measure, PASI 75, was compared with
the multidimensional SPC for pooled retrospective data
from the three studies (ACD 2058, 2059, and 2390). This
showed that 27.3% of patients treated with efalizumab
achieved PASI 75 at week 12, while 39.4% of patients
achieved SPC (Figure 2).
Discussion and conclusion
Efalizumab has been studied in more than 3500 patients.
This extensive database offers an ideal source of informa-
tion for assessing traditional measures of efficacy, and
generating new measures of benefit to assess whether a
patient's psoriasis is controlled. The SPC assessment
moves away from an approach focused primarily on treat-
ment difference in PASI 75 response in isolation, to an
approach that would further characterize each patient's
response to treatment, leading to a better understanding
of the benefit:risk that should be expected in psoriasis
treatment.
Using conventional, uni-dimensional assessment meas-
ures such as PASI 75 and DLQI, efalizumab has already
been demonstrated to be significantly more effective than
placebo. However, the use of these physician- or patient-
assessed scales either alone, or independently of each
other, does not accurately demonstrate the multidimen-
sional effect that efalizumab has in safely controlling pso-
riasis. Studies indicate that there is a need to consider
psoriasis and its treatment not just in terms of objective
assessments of lesion severity, but also in terms of the
impact of the disease on patients' lives [16,17]. The inclu-
sion of the safety component in the SPC endpoint allows
a simple benefit:risk assessment to be made, as the end-
point describes the proportion of patients who had bene-
fit without major side effects.
We applied this new outcome measure – SPC – using
week 12 data obtained from studies that had already been
completed and analyzed using conventional uni-dimen-
sional measures such as PASI, and evaluated SPC prospec-
tively in a new study (IMP 24011) that had not been
completed at the time SPC was described.
A favorable overall benefit:risk profile as determined by
the SPC endpoint was confirmed in nearly 40% of all the
patients treated with efalizumab for 12 weeks. Using SPC
in both prospective and retrospective clinical trial analy-
ses, efalizumab consistently demonstrated superiority
over placebo, demonstrating that many patients achieve
disease control without major safety issues, and at the
same time experience an improved quality of life. Impor-
tantly, efalizumab was similarly effective in high-need
patients. Also, even amongst those patients who did not
manage to achieve SPC, approximately 9% achieved PASI
75 after 12 weeks of treatment with efalizumab 1.0 mg/kg,
compared with less than 1% of patients on placebo.
Improvement in the management of psoriasis is particu-
larly welcome as the impact of the disease, particularly
among high-need patients, and shortcomings of current
treatments are becoming more widely recognized. Current
management of patients with moderate-to-severe plaque
psoriasis involves systemic therapies, such as cyclosporin,
methotrexate, acitretin and PUVA, which are associated
with treatment-limiting systemic cumulative toxicities.
The use of biological agents such as efalizumab that mod-
ulate the activation of T-cells and their migration into the
dermal and epidermal tissues may provide more targeted
therapy with an improved safety profile. Our findings,
and those of prior trials of efalizumab, support this con-
cept and demonstrate promising opportunities to
improve therapy. The observations of substantial disease
Table 3: Prospective SPC results at week 12
Study IMP 24011[15] Treatment Group Safe Psoriasis Control (SPC)*
Total study group Placebo (n = 165) 12 (7.3 %)
Efalizumab 1.0 mg/kg/wk (n = 329) 113 (34.3 %)
High need group Placebo (n = 117) 4 (3.4 %)
Efalizumab 1.0 mg/kg/wk (n = 221) 73 (33.0 %)
* SPC is defined by PASI <= 8 and DLQI <= 6 and No SAEs and No Severe AEs related to Study Drug and not withdrawnBMC Dermatology 2006, 6:8 http://www.biomedcentral.com/1471-5945/6/8
Page 5 of 6
(page number not for citation purposes)
improvements with little evidence of systemic toxicity are
consistent with those in previous reports.
The endpoints used in trials should align with the treat-
ment goals of clinical practice. SPC includes all relevant
assessments (physician, patient, and safety) and is a more
robust way of estimating the true benefit:risk ratio of pso-
riasis treatment. The findings of this analysis using the
SPC show that efalizumab provides significant improve-
ments safely in patients with moderate-to-severe plaque
psoriasis, and particularly in difficult-to-treat, high-need
patients.
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Patients achieving SPC on efalizumab at week 12.
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